



## Natco Pharma Limited

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.  
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243  
CIN : L24230TG1981PLC003201, www.natcopharma.co.in

21<sup>st</sup> October, 2022

Corporate Relationship Department  
M/s. BSE Ltd.  
Dalal Street, Fort  
Mumbai 400 001

Manager – Listing  
M/s. National Stock Exchange of India Ltd  
“Exchange Plaza”, Bandra – Kurla Complex  
Bandra (E) Mumbai 400 051

Scrip Code: 524816

Scrip Code: NATCOPHARM

Dear Sir / Madam,

Please find enclose herewith the Disclosure under Regulation 30 of SEBI (LODR) Regulations 2015 for your information.

Thanking you

Yours faithfully  
For NATCO Pharma Limited

Ch. Venkat Ramesh  
Company Secretary &  
Compliance Officer



## Natco Pharma Limited

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.  
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243  
CIN : L24230TG1981PLC003201, [www.natcopharma.co.in](http://www.natcopharma.co.in)

**Ref: PR/ 11 /2022-23**

**21<sup>st</sup> October, 2022**

### **Legal update**

Natco Pharma Limited (NSE: NATCOPHARM; BSE: 524816) would like to inform that FMC Corporation and FMC Singapore have served a copy of appeal on Natco. The Appeal is against the well-reasoned and clear judgement of the Hon'ble High Court of Delhi dated 19<sup>th</sup> September, 2022 which enabled Natco to launch its CTPR (Chlorantraniliprole) products.

Natco is confident of its case and is confident of its success in the appeal.

---

For NATCO Pharma Limited

Ch. Venkat Ramesh  
Company Secretary &  
Compliance Officer